Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients

Journal of Urology

Volumn 155, Issue 1, 1996, Pages 232-237

  Noldus, Joachim ^a   Stamey, Thomas A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Neoplasm staging; Prostate; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CLINICAL FEATURE; CORRELATION FUNCTION; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AUTOANALYSIS; HUMAN; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SUPPORT, NON-U.S. GOV'T;

EID: 0029656004     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66602-3     Document Type: Article

References (35)

1. Iwakiri, J., Grandbois, K., Wehner, N., Graves, H. C. B. and Stamey, T.: An analysis for urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J. Urol., 149: 783, 1993.
2. Oesterling, J. E., Chan, D. W., Epstein, J. I., Kimball, A. W., Jr., Bruzek, D. J., Rock, R. C., Brendler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139: 766, 1988.
3. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, R., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
4. Stamey, T. A., Kabalin, J. N., Ferrari, M. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J. Urol., 141: 1088, 1989.
5. Stamey, T. A., Ferrari, M. K. and Schmid, H.-P.: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J. Urol., 150: 1856, 1993.
6. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
7. Zagars, G. K.: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J. Urol., 152: 1786, 1994.
8. Stamey, T. A. and Kabalin, J. N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J. Urol., 141: 1070, 1989.
9. Kuriyama, M., Wang, M. C., Papsidero, L. D., Killian, C. S., Shimano, T., Valenzuela, L., Nishiura, T., Murphy, G. P. and Chu, T. M.: Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res., 40: 4658, 1980.
10. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J Med., 317: 909, 1987.
11. Ohori, M., Wheeler, T. M. and Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer, 74: 104, 1994.
12. Blackwell, K. L., Bostwick, D. G., Myers, R. P.., Zincke, H. and Oesterling, J. E.: Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J. Urol., 151: 1565, 1994.
13. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in mean with localized prostate cancer. J. Urol., 150: 110, 1993.
14. Bluestein, D. L., Bostwick, D. G., Bergstralh, E. J. and Oesterling, J. E.: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J. Urol., 151: 1315, 1994.
15. Oesterling, J. E., Martin, S. K., Bergstralh, E. J. and Lowe, F. C.: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A., 269: 57, 1993.
16. Kabalin, J. N., McNeal, J. E., Johnstone, I. M. and Stamey, T. A.: Serum PSA and the biologic progression of prostate cancer. Urology, 46: 65, 1995.
17. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
18. Lilja, H.: Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol. Clin. N. Amer., 20: 681, 1993.
19. Stamey, T. A.: Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology, 45: 173, 1995.
20. McNeal, J. E., Villers, A. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer, 66: 1225, 1990.
21. Chodak, G. W.: Questioning the value of screening for prostate cancer in asymptomatic men. Urology, 42: 116, 1993.
22. Catalona, W. J.: Screening for prostate cancer: enthusiasm. Urology, 42: 113, 1993.
23. Kleer, E. and Oesterling, J. E.: PSA and staging of localized prostate cancer. Urol. Clin. N. Amer., 20: 695, 1993.
24. Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143: 747, 1990.
25. Palken, M., Cobb, O. E., Warren, B. H. and Hoak, D. C.: Prostate cancer: correlation of digital rectal examination, transrectal ultrasound and prostate specific antigen levels with tumor volumes in radical prostatectomy specimens. J. Urol., 143: 1155, 1990.
26. Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol, 142: 1011, 1989.
27. Myrtle, J. F., Klimley, P. G., Ivor, P. G. and Brun, J. F.: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. Adv. Cancer Diag., Hybritech, Inc., 1986.
28. Stamey, T. A., Ekman, P. E., Blankenstein, M. A., Cooper, E. H., Kontturi, M., Lilja, H., Oesterling, J. E., Stenman, U. H. and Turkes, A.: Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Scand. J. Nephrol., suppl., 162: 73, 1994.
29. Stamey, T. A., Dietrick, D. D. and Issa, M. M.: Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J. Urol., 149: 510, 1993.
30. McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Amer. J. Surg. Path., 12: 897, 1988.
31. Benson, M. C., Whang, I. S., Pantuck, A., Ring, K., Kaplan, S. A., Olsson, C. A. and Cooner, W. H.: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol., part 2, 147: 815, 1992.
32. Seaman, E., Whang, I. S., Olsen, C. A., Katz, A. Cooner, W. H. and Benson, M. C.: PSA density (PSAD). Role in patient evaluation and management. Urol. Clin. N. Amer., 20: 653, 1993.
33. Brawer, M. K., Aramburu, E. A. G., Chen, G. L., Preston, S. D. and Ellis, W, J.: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J. Urol., 150: 369, 1993.
34. Stamey, T. A.: Making the most out of six systematic sextant biopsies. Urology, 45: 2, 1995.
35. Terris, M. K, Haney, D. J., Johnstone, I. M., McNeal, J. E. and Stamey, T. A.: Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound and systematic sextant biopsies. Urology, 45: 75, 1995.